Abbott Laboratories Corporation

Sage R&d

Other

Sage R&d, a Partnership

Shie-Ming Hwang

Pradip Mukerji

Yung-Sheng Huang

Steven N Anderson

Jonathan A Meulbroek

Jim-Wen Liu

Hsiu-Hsien Tsai

Terrence B Mazer

Andre Daab-Krzykowski

Timothy W Schenz

James N Chmura

Lonnie R Drayer

Glenn A Meyer

Edrick L Candler, Jr

Pai-Chu Kung

Antibacterial phosphoinositides

It has been discovered that certain phosphoinositides demonstrate antibacterial activity. Particularly, these phosphoinositides have been discovered to prevent the adhesion of,onto the nasopharyngeal cells of mammals, and, in particular, humans. Phosphoinositides useful with the present invention have the following formula:

The present invention is directed to a rice flour extract (RFE) which can be used in the prophylaxis and treatment of bacterial infections, particularly bacterial infections caused by,and to a method of preparing and using such an antibacterial rice flour extract. The anti-,rice flour extract of the present invention can be prepared from commercial food grade rice flours or non-commercial food grade rice flours.

Bioactive rice flour extract useful for treatment of haemophilus influenzae infections

This invention relates to compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to their use for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention arc derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitis C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.

Process for preparing an anti-viral medicinal product from plant extracts

Compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, are provided for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention are derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitis C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses. Preferred compositions contain the herbal ingredients AEGINETIAE HERBA, BLECHNI RHIZOMA, LESPEDEZAE HERBA, POLYGONI CUSPIDATI RHIZOMA, FORSYTHIAE FRUCTUS, and LIGUSTRI FRUCTUS, or contain the herbal ingredients AEGINETIAE HERBA, LONICERAE FLOS, PRUNELLAE SPICA, and LESPEDEZAE HERBA.

Compositions of matter useful in the treatment of viral infections

This invention relates to compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to their use for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention are derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitic C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.

Use of plant extracts for treatment of HIV, HCV and HBV infections

The attachment of H. influenzae to human cells such as oropharyngeal cells, is inhibited by aqueous extracts of the plants known as Pogostemon cablin and Agastache rugosa. The composition obtained from the aqueous extraction of the plants Pogostemon cablin, Agastache rugosa or mixtures thereof is also effective in preventing or treating Otitis media and sore throat. The plant extract may be contained in a liquid enteral product such as an infant formula or may be incorporated into lozenges, candies, chewing gums and the like. The plant extract may also be administered as a throat spray or nasally using drops or a spray. A process for the production of a medicinal product is also disclosed.

Pogostemon cablin extract for inhibiting H. influenzae adhesion and

There is disclosed liquid nutritionals with improved physical stability. The nutritionals are pourable yet able to hold minerals in suspension without sedimentation or sag. The invention comprises the use of iota-carrageenan of a concentration of between 50-1500 parts per million. The nutritional may also comprise kappa carrageenan at a concentration of less than 25% of the total concentration of iota- and kappa-carrageenan. There is further disclosed a method for preparing the liquid nutritional through the use of ultra-high temperature heat treatment.

Physical stability improvement of liquid nutritional products

A system for delivering an active substance has sustained release of the active substance in the intestinal tract. This delivery system is especially useful for an active substance such as a .beta.-lactam antibiotic which preferably has minimal exposure to the acidic environment of the stomach. Particles comprise an active ingredient disposed in a core which has at least one coating of a prolamine and one coating of an enteric compound thereon. The particles may be very small and suspended in a liquid medium.

Growing community of inventors

Columbus, OH, United States of America

Shie-Ming Hwang